Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors

Nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) inhibitors have potential as novel drugs for the (immuno)therapy of cancer. They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5’-nucleotidase (CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäkel, Laura, Schmies, Constanze C., Idris, Riham M., Luo, Xihuan, Lee, Sang-Yong, Lopez, Vittoria, Mirza, Salahuddin, Vu, The Hung, Pelletier, Julie, Sévigny, Jean, Namasivayam, Vigneshwaran, Müller, Christa E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508162/
https://www.ncbi.nlm.nih.gov/pubmed/33013365
http://dx.doi.org/10.3389/fphar.2020.01294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508162/
https://www.ncbi.nlm.nih.gov/pubmed/33013365
http://dx.doi.org/10.3389/fphar.2020.01294

Ejemplares similares